Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)
Latest Information Update: 13 Mar 2025
At a glance
- Drugs Anastrozole (Primary) ; Bevacizumab (Primary) ; Camrelizumab (Primary) ; Dalpiciclib (Primary) ; Everolimus (Primary) ; Exemestane (Primary) ; Famitinib (Primary) ; Fulvestrant (Primary) ; Fuzuloparib (Primary) ; Goserelin (Primary) ; Letrozole (Primary) ; SHR 1167 (Primary) ; SHR 6209 (Primary) ; SHR A2102 (Primary) ; SHR-A1921 (Primary) ; SHR-A2009 (Primary) ; Sorafenib (Primary) ; Trastuzumab rezetecan (Primary) ; Capecitabine; Paclitaxel; Phosphatidylinositol 3 kinase alpha inhibitors; Rivoceranib; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms Linux
- 04 Oct 2024 Arms increased from 8 to 26. Drugs SHR-A1811, bevacizumab, SHR-6209, SHR-A1921, SHR-A2009, and SHR-A2102 added newly in the trial.
- 04 Oct 2024 Planned number of patients changed from 140 to 620.
- 02 Jan 2023 Planned initiation date changed from 1 Dec 2022 to 30 Dec 2022.